(RARE) - Earnings & Price History

RARE: - 70.99, $3.00B, 2.93 (4.31%)

Sector: Healthcare - Industry: Biotechnology

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of adult inoperable tumor-induced osteomalacia patients. Its biologics product candidates also comprise recombinant human beta-glucuronidase (rhGUS), an intravenous enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protei

Past RARE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2014-11-10Ultragenyx Phar-0.45-0.542.8441.1640.9340.6242.93-0.56%4.67%4.08%243.80K
2014-08-11Ultragenyx Phar-0.41-0.4550.4449.1549.2148.7451.790.12%▲2.50%2.62%350.40K
2014-06-23Ultragenyx Phar-0.38-0.8545.4444.7744.9544.9549.520.40%▲1.09%1.50%185.20K

Login | Register
Thursday Jul 20, 2017   EST
Enter a Ticker:

Economic Calendar

Jobless Claims 8:30 AM ET Philadelphia Fed Business Outlook Survey 8:30 AM ET Bloomberg Consumer Comfort Index 9:45 AM ET Leading Indicators 10:00 AM ET EIA Natural Gas Report 10:30 AM ET 3-Month Bill Announcement 11:00 AM ET 6-Month Bill Announcement 11:00 AM ET 2-Yr FRN Note Announcement 11:00 AM ET 2-Yr Note Announcement 11:00 AM ET 5-Yr Note Announcement 11:00 AM ET 7-Yr Note Announcement 11:00 AM ET 10-Yr TIPS Auction 1:00 PM ET Fed Balance Sheet 4:30 PM ET Money Supply 4:30 PM ET 

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color